Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $34 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Catalyst Pharmaceuticals (NASDAQ:CPRX) and maintained a $34 price target.
March 22, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald reaffirmed an Overweight rating on Catalyst Pharmaceuticals with a $34 price target.
The reiteration of an Overweight rating and maintenance of a $34 price target by a reputable analyst firm like Cantor Fitzgerald could instill confidence among investors and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100